menu search

ACON / Aclarion skyrockets on positive trial data for lower back pain intelligence platform

Aclarion skyrockets on positive trial data for lower back pain intelligence platform
Aclarion shares skyrocketed after the company published data from a two-year trial that demonstrated improved surgical outcomes for discogenic lower back pain (DLBP) surgeries at chemically painful lumbar discs identified by Nociscan, the company's intelligence platform for measuring pain biomarkers in the lumbar spine. Nociscan receives magnetic resonance spectroscopy (MRS) data from an MRI machine and uses its proprietary signal processing techniques to extract and quantify chemical biomarkers associated with disc pain, according to Aclarion. Read More
Posted: Apr 24 2023, 11:46
Author Name: Proactive Investors
Views: 082544

ACON News  

Aclarion skyrockets on positive trial data for lower back pain intelligence platform

By Proactive Investors
April 24, 2023

Aclarion skyrockets on positive trial data for lower back pain intelligence platform

Aclarion shares skyrocketed after the company published data from a two-year trial that demonstrated improved surgical outcomes for discogenic lower b more_horizontal


Search within

Pages Search Results: